Ito, Tetsuhide
Honma, Yoshitaka
Hijioka, Susumu
Kudo, Atsushi
Fukutomi, Akira
Nozaki, Akira
Kimura, Yasutoshi
Motoi, Fuyuhiko
Isayama, Hiroyuki
Komoto, Izumi
Hisamatsu, Seiichi
Nakajima, Akihiro
Shimatsu, Akira
Funding for this research was provided by:
Teijin Pharma Limited
Article History
Received: 10 March 2017
Accepted: 4 April 2017
First Online: 3 May 2017
Compliance with ethical standards
:
: Seiichi Hisamatsu and Akihiro Nakajima are employees of Teijin Pharma Limited, and hold Teijin Pharma Limited stock. Tetsuhide Ito and Akira Shimatsu have received research funding from Teijin Pharma Limited. Yoshitaka Honma, Susumu Hijioka, Atsushi Kudo, Akira Fukutomi, Akira Nozaki, Yasutoshi Kimura, Fuyuhiko Motoi, Hiroyuki Isayama, and Izumi Komoto have no potential conflicts of interest to disclose.
: This work was supported by the Pharmaceutical Development Department I and the Pharmaceutical Development Administration Department, Teijin Pharma Limited in Tokyo, Japan.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This protocol was approved by the Institutional Review Board (IRB) of each study site. Written informed consent was obtained from all patients before screening.